A Case–Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment

Qi, Chunhou; Gao, Hong‐Fei; Li, Shankai; Zong, Huanbo; Hao, Hongjun; Zhang, Lei

doi:10.1089/gtmb.2019.0111

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its main mechanism is that reduced folate methotrexate is metabolized by intracellular folylpolyglutamate synthase to produce a series of polyglutamate compounds with stronger inhibition of thymidylate synthetase than raltitrexed, which can produce antitumor effects by inhibiting cell DNA synthesis. 28 Note: Data are expressed as n (%). Disease control rate was defined as the sum of the proportion of CR, PR, and SD.…”

Section: Adverse Eventsmentioning

confidence: 99%

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Sun

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Aim: This study aimed to evaluate efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC) using real-world evidence.Methods: All eligible HCC cases were collected from multiple centers in Chongqing, China, from January 2013 to December 2018 and divided into the raltitrexed group (raltitrexed + lobaplatin + pirarubicin) and control group (lobaplatin + pirarubicin).Propensity score matching (PSM) with a 1:1 ratio was used to eliminate the imbalance of potential confounding factors between groups. The primary end-point was overall survival (OS) and the secondary end-points were progression-free survival (PFS) and disease control rate. Results:The median follow-up period for patients in the raltitrexed and control groups was 8.7 and 5.9 months, respectively. After PSM, median OS was 10.0 months in the raltitrexed group and 7.0 months in the control group (p = 0.002). The 6-month, 1-year, and 2-year OS rates of the raltitrexed group were significantly higher than those of the control group (78.2% vs. 60.9%, p = 0.010; 43.5% vs. 22.8%, p = 0.030; and 17.4% vs. 2.2% p = 0.001, respectively). Multivariate analysis of these propensity score-matched HCC patients revealed treatment, age, tumor size, lipiodol accumulation, and the number of TACE cycles as independent predictors of OS (all p < 0.05). The disease control rate of the raltitrexed and control groups was 87.4% and 65.8%, respectively (p < 0.001). Conclusions:Raltitrexed-based TACE can prolong the OS of patients with intermediate and advanced HCC in a real-world clinical setting, and is safe and tolerable.

show abstract

Section: Adverse Eventsmentioning

confidence: 99%

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Sun

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

show abstract

A Case–Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment

Cited by 1 publication

References 19 publications

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Contact Info

Product

Resources

About